+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
45.5900
2.5581
1.9173
.4703
2.3477
43.3579
High
73.8019
4.5155
No
Yes
No
Yes
Yes
Yes
0.0
No
No
No
No
Quinidine, CAS number 56-54-2, is a long-established and clinically widely used natural antiarrhythmic drug. As a stereoisomer of quinine, quinidine was originally isolated from the bark of the Cinchona spp. tree and has long been used to treat arrhythmias and malaria. With the development of molecular pharmacology and medicinal chemistry, the pharmacological mechanisms of quinidine have gradually become clearer, especially its role in cardiac electrophysiological regulation. In recent years, quinidine has not only been proven as an effective cytochrome P450db inhibitor and potassium channel blocker, but also shows potential for inducing apoptosis, broadening its research and application fields.
This paper will systematically review the chemical structure and physicochemical properties of quinidine, its plant origin and extraction methods, pharmacological activity and mechanism of action, delve into its molecular targets and druggable characteristics, and, combined with pharmacokinetic data, anticipate its clinical application prospects and future directions, providing detailed reference materials for researchers in the field of natural product pharmacology.
The chemical name of quinidine is (R)-α-ethyl-6-methoxy-4-quinoline methanol, with a molecular formula of C20H24N2O2 and a molecular weight of 324.4240. Its structure belongs to the quinine alkaloids, featuring typical quinoline rings and side-chain alcohol groups. The molecular structure of quinidine contains multiple chiral centers, giving it specific stereochemical properties closely related to its biological activity.
In terms of physicochemical properties, the LogP value of quinidine is 2.5581, indicating moderate lipid solubility, which is beneficial for transmembrane absorption and distribution. Its topological polar surface area (TPSA) is 45.59 Ų, indicating moderate polarity and favorable oral bioavailability. Water solubility is 0.4703 mg/mL, making it a low to medium solubility compound. Quinidine can effectively cross the blood-brain barrier (BBB), which is related to its high lipophilubility and low polarity. It is worth noting that quinidine is an hERG (human cardiac potassium channel) inhibitor, a property closely related to its antiarrhythmic activity and potential cardiotoxicity. Additionally, quinidine was negative in the Ames test, indicating a low genotoxicity risk.
Quinidine mainly comes from the bark of the genus Cinchona spp., especially species like Cinchona officinalis and Cinchona ledgeriana. The cinchona tree is native to the Andes Mountains of South America and is a natural source of traditional antimalarial drugs quinine and quinidine. The bark contains various alkaloids, with quinidine being one of the most important active components.
The extraction process usually uses acid-base extraction. Fresh or dried cinchona bark is first soaked in a dilute acid (such as hydrochloric acid) solution to form quinidine salts and increase its water solubility. Subsequently, alkalization (such as sodium hydroxide solution) precipitates quinidine in the form of a free base, and liquid-liquid extraction is performed using organic solvents (such as ether or chloroform). The extract undergoes steps such as concentration and recrystallization to obtain high-purity quinidine. In modern processes, supercritical fluid extraction and high-performance liquid chromatography (HPLC) purification technologies are also applied to the extraction and purification of quinidine, improving product purity and yield.
As a classic antiarrhythmic drug, quinidine is mainly used to treat ventricular and supraventricular arrhythmias. Its pharmacological activity covers the regulation of various ion channels, especially the blocking effects of potassium (K+ channel) and sodium (Na+ channel).
Antiarrhythmic activity
Quinidine restores normal heart rhythm by blocking various ion channels on the membranes of myocardial cells, extending the duration of action potentials and suppressing abnormal electrical activity. Its main targets include KCNH2 (hERG), KCNQ1, SCN5A (cardiac sodium channel Nav1.5), CACNA1C (L-type calcium channel), KCNE1, KCNE2, and RYR2 (myocardial sarcoplasmic reticulum calcium release channel). Among these, quinidine blocked the hERG channel particularly well, with an IC50 of about 19.9 μM, prolonging the cardiac repolarization process and preventing arrhythmias.
Cytochrome P450db inhibition
Quinidine is a selective cytochrome P450db inhibitor that affects the enzyme system of drug metabolism, potentially leading to drug-drug interactions. This property requires attention in clinical use, especially when used in combination with other drugs that depend on P450 metabolism.
Induces apoptosis
Recent studies have found that quinidine can induce apoptosis in various cell types, suggesting its potential applications in oncology and cell biology. The mechanisms of its apoptosis induction may involve ion channel regulation, mitochondrial dysfunction, and oxidative stress pathways.
Malaria research and applications
Although quinidine is now rarely used alone in malaria treatment, its antimalarial activity is still widely studied, especially in mechanisms of resistance and the development of novel antimalarial drugs, where quinidine plays an important role as a model compound.
The mechanism of action of quinidine is complex, involving regulation of various ion channels and enzyme systems:
KCNH2 (hERG) channel blockage
The hERG channel mediates the rapid delayed reduction potassium current (IKr) of the heart, which is crucial for cardiac repolarization. Quinidine binds to hERG channels to suppress IKr currents, extend the action potential duration, and prevent arrhythmias. Although this effect is effective, it may also prolong the QT interval and increase the risk of arrhythmias.
KCNQ1/KCNE1 channel adjustment
The slow-delayed reduced potassium current (IKs) channel composed of KCNQ1 and the helper subunit KCNE1 is also a target for quinidine, regulating the cardiomyocyte repolarization process.
SCN5A (Nav1.5) sodium channel blockade
Quinidine blocks myocardial sodium channels, reduces sodium ion influx, lowers myocardial cell excitability, and inhibits abnormal conduction.
CACNA1C (L-type calcium channels) inhibition
By inhibiting L-type calcium channels, quinidine reduces calcium ion influx, affecting myocardial contraction and electrical activity.
RYR2 regulation
Quinidine regulates the RYR2 calcium release channel in the sarcoplasmic reticulum, affects intracardiac calcium homeostasis, and participates in antiarrhythmic effects.
Cytochrome P450db is inhibited
Quinidine selectively inhibits the P450db enzyme, interferes with drug metabolism, and affects pharmacokinetics.
Apoptosis induction mechanism
Quinidine-induced apoptosis may be achieved by regulating ion channel-mediated intracellular calcium homeostasis, activating mitochondrial pathways, and oxidative stress responses.
Quinidine has good oral bioavailability, moderate LogP values, and low TPSA, which facilitates membrane permeation and system distribution. Its molecular weight of 324.4240 complies with the "drug similarity" principle in drug design. It has low water solubility but is sufficient to meet the dissolution requirements of oral formulations.
Quinidine can effectively cross the blood-brain barrier, suggesting it may also have certain activity or side effects in the central nervous system. As an hERG channel inhibitor, although it enhances antiarrhythmic effects, it also carries potential cardiotoxicity risks and must be strictly controlled in clinical dosage and administration regimens.
Pharmacokinetic studies show that quinidine is rapidly absorbed orally and has a high plasma protein binding rate, mainly metabolized and excreted by the liver. The metabolic pathway involves the cytochrome P450 enzyme system, especially the P450db subtype. Its half-life is moderate, making it suitable for clinical treatment.
The Ames test result was negative, indicating a low genotoxicity risk and good safety for quinidine.
As a first-line antiarrhythmic drug, quinidine is especially suitable for treating ventricular arrhythmias and paroxysmal supraventricular tachycardia. Its multi-target mechanism gives it unique advantages in the treatment of complex arrhythmias. In the future, with deeper understanding of its molecular targets and mechanisms of action, quinidine is expected to reduce cardiotoxicity and improve treatment selectivity through structural modification and dosage form optimization.
In addition, quinidine's inhibitory effect on cytochrome P450db provides an important model for drug interaction research, guiding rational clinical medication. Its potential to induce apoptosis also suggests the potential application of quinidine in the antitumor field, warranting further exploration.
In malaria research, although quinidine is no longer the first-line drug, studies on its antimalarial mechanisms and molecular mechanisms related to drug resistance remain of great significance, aiding the development of novel antimalarial drugs.
Future research should focus on structural optimization of quinidine, reducing cardiotoxicity associated with hERG channel inhibition, expanding its indications, and integrating modern drug delivery technologies to improve clinical efficacy and safety.
As a classic natural antiarrhythmic drug, quinidine plays an important role in clinical arrhythmia treatment due to its multi-target regulatory capabilities and good oral activity. Its complex pharmacological mechanisms include blocking potassium, sodium, and calcium channels, as well as inhibition of cytochrome P450db, reflecting the multidimensional pharmacological characteristics of natural products.
Despite the risk of cardiotoxicity, quinidine remains one of the indispensable drugs in arrhythmia treatment. In the future, through in-depth molecular mechanism research and reasonable structural modification, its safety and efficacy are expected to be further improved, expanding its clinical application fields. As a model for pharmacology research on natural products, quinidine's achievements not only enrich the knowledge system of cardiovascular pharmacology but also provide a valuable theoretical and practical foundation for new drug development.
Shenshuai
Wenjing
Hedandan
